New agreement secures 66% reduction in cost of rifapentine, which prevents ‘latent’ TB from becoming active
The price of a drug crucial to prevent tuberculosis is to be slashed by two-thirds in a deal that could stop millions from developing the disease.
TB is the leading cause of death from infectious disease worldwide, killing 1.5 million people a year, according to the latest World Health Organization (WHO) global TB report.
This post was syndicated from Health | The Guardian. Click here to read the full text on the original website.
Leave a Reply